What is Acurx Pharmaceuticals Inc's earnings per share (EPS)?

Acurx Pharmaceuticals Inc (ACXP) reported diluted earnings per share of $-5.32 for fiscal year 2025. This represents a 69.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Acurx Pharmaceuticals Inc Financials

ACXP

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Acurx Pharmaceuticals Inc (ACXP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ACXP FY2025 2026-05-11

No reported revenue leaves external financing, not operations, as the core mechanism keeping the business funded.

FY2025 looks stronger because cash recovered to $7.6M, but that came with $10.6M of financing cash rather than operating self-funding. Across FY2023-FY2025, repeated capital raises and still-negative operating cash flow show a runway reset, while FY2024’s compressed equity cushion helps explain why the balance-sheet improvement is financing-driven rather than operational.

The smaller FY2025 loss reflects a lower expense base, not market traction: R&D fell to $1.8M from $5.4M, and SG&A also moved lower. That makes the improvement a story of spending pace and program timing, not one where customers have started absorbing fixed costs.

With $7.6M of cash against $2.4M of total liabilities, balance-sheet obligations look lighter than cash-consumption pressure. The operating model therefore behaves like a cash-runway equation: financing extends time, but cumulative losses keep book equity dependent on new capital.

Financial Health Signals

Financial health score pending refresh

We are recalculating Acurx Pharmaceuticals Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

2/5

Acurx Pharmaceuticals Inc passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.85x

For every $1 of reported earnings, Acurx Pharmaceuticals Inc generates $0.85 in operating cash flow (-$6.8M OCF vs -$8.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$8.0M

YoY+43.5%

Acurx Pharmaceuticals Inc reported -$8.0M in net income in fiscal year 2025. This represents an increase of 43.5% from the prior year.

EPS (Diluted)

$-5.32

YoY+69.5%

Acurx Pharmaceuticals Inc earned $-5.32 per diluted share (EPS) in fiscal year 2025. This represents an increase of 69.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$7.6M

YoY+103.8%

5Y CAGR+18.9%

Acurx Pharmaceuticals Inc held $7.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+175.8%

Acurx Pharmaceuticals Inc had 2M shares outstanding in fiscal year 2025. This represents an increase of 175.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-151.2%

YoY+2141.5pp

5Y CAGR+19.1pp

Acurx Pharmaceuticals Inc's ROE was -151.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2141.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.8M

YoY-66.1%

5Y CAGR-3.6%

Acurx Pharmaceuticals Inc invested $1.8M in research and development in fiscal year 2025. This represents a decrease of 66.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ACXP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.8M-66.1%	$5.4M-10.6%	$6.0M+27.1%	$4.8M+134.2%	$2.0M-7.8%	$2.2M
SG&A Expenses	$6.3M-28.2%	$8.7M+2.2%	$8.5M+16.3%	$7.3M+3423.6%	$208K-91.3%	$2.4M
Operating Income	-$8.1M+42.7%	-$14.1M	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	$0	N/A	$0
Net Income	-$8.0M+43.5%	-$14.1M+3.3%	-$14.6M-20.5%	-$12.1M+5.1%	-$12.7M-177.1%	-$4.6M
EPS (Diluted)	$-5.32+69.5%	$-17.45	$-1.15-2.7%	$-1.12+24.8%	$-1.49-101.4%	$-0.74

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$341K	N/A	$430K-18.0%	$524K-12.5%	$599K	N/A	$1.2M-34.4%	$1.8M
SG&A Expenses	$1.4M	N/A	$1.6M-8.4%	$1.7M+10.6%	$1.6M	N/A	$1.6M-29.1%	$2.3M
Operating Income	-$1.7M	N/A	-$2.0M+10.6%	-$2.3M-4.3%	-$2.2M	N/A	-$2.8M+31.4%	-$4.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.7M	N/A	-$2.0M+11.3%	-$2.2M-4.5%	-$2.1M	N/A	-$2.8M+31.5%	-$4.1M
EPS (Diluted)	$-0.62	N/A	$-1.23+34.9%	$-1.89	$-2.15	N/A	$-3.45+33.8%	$-5.21

ACXP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$7.7M+99.3%	$3.9M-50.0%	$7.7M-17.8%	$9.4M-29.3%	$13.3M+311.1%	$3.2M
Current Assets	N/A	$3.9M-50.0%	$7.7M-17.8%	$9.4M-29.3%	$13.3M	N/A
Cash & Equivalents	$7.6M+103.8%	$3.7M-50.4%	$7.5M-18.0%	$9.1M-29.7%	$13.0M+308.1%	$3.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M-25.3%	$3.2M+6.6%	$3.0M+47.6%	$2.1M+144.3%	$844K+61.5%	$522K
Current Liabilities	$2.4M-25.3%	$3.2M+6.6%	$3.0M+47.6%	$2.1M+144.3%	$844K+78.6%	$473K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.3M+756.5%	$615K-86.8%	$4.7M-36.2%	$7.3M-41.1%	$12.4M+359.4%	$2.7M
Retained Earnings	-$75.3M-11.8%	-$67.3M-26.5%	-$53.2M-37.7%	-$38.6M-45.6%	-$26.5M-92.4%	-$13.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$9.5M+24.1%	$7.7M+26.0%	$6.1M-0.9%	$6.2M+28.1%	$4.8M+24.6%	$3.9M-35.5%	$6.0M-9.1%	$6.6M
Current Assets	N/A	N/A	N/A	$6.2M+28.1%	$4.8M+24.6%	$3.9M-35.5%	$6.0M	N/A
Cash & Equivalents	$9.3M+22.5%	$7.6M+27.9%	$5.9M-2.6%	$6.1M+30.6%	$4.6M+25.3%	$3.7M-35.7%	$5.8M-9.4%	$6.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M+4.4%	$2.4M-1.9%	$2.5M-4.8%	$2.6M+3.9%	$2.5M-23.1%	$3.2M-2.3%	$3.3M+5.3%	$3.2M
Current Liabilities	$2.5M+4.4%	$2.4M-1.9%	$2.5M-4.8%	$2.6M+3.9%	$2.5M-23.1%	$3.2M-2.3%	$3.3M+5.3%	$3.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.0M+33.1%	$5.3M+44.9%	$3.6M+2.0%	$3.6M+54.3%	$2.3M+275.8%	$615K-76.9%	$2.7M-22.3%	$3.4M
Retained Earnings	-$77.0M-2.2%	-$75.3M-2.1%	-$73.7M-2.8%	-$71.7M-3.2%	-$69.5M-3.2%	-$67.3M-4.3%	-$64.5M-4.6%	-$61.7M

ACXP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.8M+34.6%	-$10.4M-5.9%	-$9.8M-29.9%	-$7.5M-50.4%	-$5.0M-49.6%	-$3.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$10.6M+60.8%	$6.6M-19.0%	$8.2M+120.9%	$3.7M-75.0%	$14.8M+265.9%	$4.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$1.4M-18.8%	-$1.2M+37.0%	-$1.9M-12.6%	-$1.7M+18.6%	-$2.1M+8.8%	-$2.3M-2.8%	-$2.2M+24.0%	-$2.9M
Capital Expenditures	$110K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$1.5M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$3.1M+9.6%	$2.8M+64.4%	$1.7M-44.2%	$3.1M+3.4%	$3.0M+1436.2%	$195K-87.8%	$1.6M+397.0%	$320K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ACXP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-151.2%+2141.5pp	-2292.7%-1980.4pp	-312.4%-147.1pp	-165.3%-62.6pp	-102.7%+67.6pp	-170.3%
Return on Assets	-103.6%+262.0pp	-365.6%-176.5pp	-189.1%-60.1pp	-129.0%-32.8pp	-96.2%+46.5pp	-142.7%
Current Ratio	N/A	1.19-1.3	2.53-2.0	4.55-11.2	15.71	N/A
Debt-to-Equity	0.46-4.8	5.27+4.6	0.65+0.4	0.28+0.2	0.07-0.1	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-24.0%	N/A	-54.8%+8.2pp	-63.0%+30.0pp	-93.0%	N/A	-105.9%+14.3pp	-120.3%
Return on Assets	-17.6%	N/A	-32.6%+3.8pp	-36.5%+8.2pp	-44.7%	N/A	-47.2%+15.5pp	-62.6%
Current Ratio	N/A	N/A	N/A	2.38+0.4	1.93+0.7	1.19-0.6	1.80	N/A
Debt-to-Equity	0.36-0.1	0.46-0.2	0.68-0.0	0.73-0.4	1.08-4.2	5.27+4.0	1.25+0.3	0.92
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Nucana NCNA

$5.6M

Artelo Biosciences Inc ARTL

$3.8M

TNF Pharmaceuticals TNFA

$9.6M

Aim Immunotech AIM

$7.8M

Pharmacyte Biotech Inc PMCB

$7.5M

Frequently Asked Questions

Is Acurx Pharmaceuticals Inc profitable?

No, Acurx Pharmaceuticals Inc (ACXP) reported a net income of -$8.0M in fiscal year 2025.

What is Acurx Pharmaceuticals Inc's return on equity (ROE)?

Acurx Pharmaceuticals Inc (ACXP) has a return on equity of -151.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Acurx Pharmaceuticals Inc's operating cash flow?

Acurx Pharmaceuticals Inc (ACXP) generated -$6.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Acurx Pharmaceuticals Inc's total assets?

Acurx Pharmaceuticals Inc (ACXP) had $7.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Acurx Pharmaceuticals Inc spend on research and development?

Acurx Pharmaceuticals Inc (ACXP) invested $1.8M in research and development during fiscal year 2025.

How many shares does Acurx Pharmaceuticals Inc have outstanding?

Acurx Pharmaceuticals Inc (ACXP) had 2M shares outstanding as of fiscal year 2025.

What is Acurx Pharmaceuticals Inc's debt-to-equity ratio?

Acurx Pharmaceuticals Inc (ACXP) had a debt-to-equity ratio of 0.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Acurx Pharmaceuticals Inc's return on assets (ROA)?

Acurx Pharmaceuticals Inc (ACXP) had a return on assets of -103.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Acurx Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Acurx Pharmaceuticals Inc (ACXP) had $7.6M in cash against an annual operating cash burn of $6.8M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Acurx Pharmaceuticals Inc's Piotroski F-Score?

Acurx Pharmaceuticals Inc (ACXP) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Acurx Pharmaceuticals Inc's earnings high quality?

Acurx Pharmaceuticals Inc (ACXP) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.